The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kropacheva E.S.

Institute of Cardiology named after A.L. Myasnikov of National Medical Research Center for Cardiology, Moscow, Russia

Zemlyanskaya O.A.

Institute of the Cardiology named after A.L. Myasnikov of National Medical Research Center for Cardiology, Moscow, Russia

Dobrovol'skiĭ A.B.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Panchenko E.P.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Prognostic value of the SAMe-TT2R2 index and Charlson Comorbidity Index for the non-target anticoagulation and risk of thrombotic events in warfarin-treated patients (results of 10-years prospective study)

Authors:

Kropacheva E.S., Zemlyanskaya O.A., Dobrovol'skiĭ A.B., Panchenko E.P.

More about the authors

Journal: Russian Cardiology Bulletin. 2019;14(1): 23‑32

DOI: 10.17116/Cardiobulletin20191401123

Read: 1620 times

Download PDF (RU)
Contact the author
Table of contents

PROGNOSTIC VALUE OF THE SAME-TT2R2 INDEX AND CHARLSON COMORBIDITY INDEX FOR THE NON-TARGET ANTICOAGULATION AND RISK OF THROMBOTIC EVENTS IN WARFARIN-TREATED PATIENTS (RESULTS OF 10-YEARS PROSPECTIVE STUDY)
PROGNOSTIC VALUE OF THE SAME-TT2R2 INDEX AND CHARLSON COMORBIDITY INDEX FOR THE NON-TARGET ANTICOAGULATION AND RISK OF THROMBOTIC EVENTS IN WARFARIN-TREATED PATIENTS (RESULTS OF 10-YEARS PROSPECTIVE STUDY)

To cite this article:

Kropacheva ES, Zemlyanskaya OA, Dobrovol'skiĭ AB, Panchenko EP. Prognostic value of the SAMe-TT2R2 index and Charlson Comorbidity Index for the non-target anticoagulation and risk of thrombotic events in warfarin-treated patients (results of 10-years prospective study). Russian Cardiology Bulletin. 2019;14(1):23‑32. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20191401123

Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Correlation of soma­tic status and postoperative complications in como­rbid patients with loca­lly adva­nced colon cancer. Piro­gov Russian Journal of Surgery. 2025;(12):109-118
Abstract:

Warfarin therapy requires that at least 70% INR achieve target range 2.0—3.0. Stability of INR values is determined by many factors. It is difficult to identify the patients, who have a high likelihood of lacking to achieve the target INR. Among 250 patients with atrial fibrillation, receiving warfarin, the number of patients with SAMe-TT2R2 >2 was 11.6%. Comparison of the SAMe-TT2R2 index and Charlson Comorbidity Index showed a comparable prognostic values for TTR <70% (AUC=0.650 and AUC=0.655 respectively, p=0.9209 for difference). 1 point for SAMe-TT2R2 index and 3 points for Charlson Comorbidity Index were diagnostic criteria. Comparison of the SAMe-TT2R2 index and Charlson Comordidity Index showed a comparable prognostic values for all ischemic strokes (AUC=0.616 and AUC=0.692 respectively, p=0.2874 for difference). Charlson Comordidity Index showed the advantage of the SAMe-TT2R2 index in accessing the frequency of cardio-vascular death (AUC=0.835 and AUC=0.701 respectively, p=0.0066 for difference) and total end point, included all fatal and non-fatal thrombotic events (AUC=0,769 and AUC=0,671 respectively, p=0.0395 for difference).

Keywords:

warfarin
target INR
TTR
SAMe-TT2R2 index
Charlson Comorbidity Index

Authors:

Kropacheva E.S.

Institute of Cardiology named after A.L. Myasnikov of National Medical Research Center for Cardiology, Moscow, Russia

Zemlyanskaya O.A.

Institute of the Cardiology named after A.L. Myasnikov of National Medical Research Center for Cardiology, Moscow, Russia

Dobrovol'skiĭ A.B.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Panchenko E.P.

Rossiĭskiĭ kardiologicheskiĭ nauchno-proizvodstvennyĭ kompleks Minzdravsotsrazvitiia RF, Moskva

Close metadata

References:

  1. 2012 Russian Scientific Society of Specialists in Clinical Electrophysiology, Arrhythmology and Cardiac Pacing, Russian Cardiology Society and the Association of Cardiovascular Surgeons of Russia Guidelines for the management of atrial fibrillation. (In Russ.).
  2. ESC Guidelines for the management of atrial fibrillation 2016. First published online: 27 August 2016. https://doi.org/10.1093/eurheartj/ehw210
  3. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):637-68. pmid:22315274. https://doi.org/10.1378/chest.11-2306
  4. White HD, Gruber M, Feyzi J, et al Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-245.
  5. Connolly SJ, Ezekowitz MD, Salim Yusuf, et al and *the RE-LY Steering Committee and Investigators «Dabigatran versus Warfarin in Patients with Atrial Fibrillation». N Engl J Med. 2009;361:1139-1151. https://doi.org/10.1056/NEJMoa090556123
  6. Manesh RP, Mahaffey KW, Jyotsna Garg, et al and the ROCKET AF Steering Committee, for the ROCKET AF Investigators. «Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation». N Engl J Med. 2011;365:883-891.
  7. Goto S, Zhu J, Liu L, et al. ARISTOTLE Investigators. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 2014;168(3):303-309. https://doi.org/10.1016/j.ahj.2014.06.005
  8. Bassand JP, Accetta G, Camm AJ, et al Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Eur Heart J. 2016;37(38):2882-2889.
  9. Tajer C, Ceresetto J, Bottaro FJ. TERRA Trial investigators. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry. Thromb Hemost. 2017;23(5):445-453. https://doi.org/10.1177/1076029615623378
  10. Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, et al Quality of oral anticoagulation with vitamin K antagonists in «real-world» patients with atrial fibrillation: a report from the prospective multicentre FANTASIIA registry. Europace. 2018;20(9):1435-1441. https://doi.org/10.1093/europace/eux314
  11. Olesen JB, Lip GY, Kamper AL, et al Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012;367:625-635.
  12. Schwammenthal Y, Bornstein N, et al Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey. Am J Cardiol. 2010;105(3):411-416. https://doi.org/10.1016/j.amjcard.2009.09.050
  13. Palareti G, Antonucci E, Migliaccio L, et al Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. Intern Emerg Med. 2017;12(8):1109-1119. https://doi.org/10.1007/s11739-017-1678-9
  14. Pivatto Junior F, Scheffel RS, Ries L. SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events. Arq Bras Cardiol. 2017;108(4):290-296. https://doi.org/10.5935/abc.20170052
  15. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest. 2013;144:1555-1563.
  16. Ruiz-Ortiz M, Bertomeu V, Cequier Á, et al. Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. Thromb Haemost. 2015;114(4):695-701. Epub 2015 Jun 9. https://doi.org/10.1160/TH15-02-0169
  17. Bernaitis N, Ching CK, Chen L, et al. The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score Predicts Warfarin Control in a Singaporean Population. J Stroke Cerebrovasc Dis. 2017;26(1):64-69. Epub 2016 Sep 23. https://doi.org/10.1016/j.jstrokecerebrovasdis.2016.08.030
  18. Liu J, Wang N, Qin L, et al Integrating genotypes in the SAMe-TT2R2 score for the prediction of anticoagulation control in Chinese patients with atrial fibrillation on warfarin. Int J Cardiol. 2017;241:358-363. Epub 2017 Apr 29. https://doi.org/10.1016/j.ijcard.2017.04.092
  19. Chan PH, Hai JJ, Chan EW, et al. Use of the SAMe-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. PLoS One. 2016;11(3):e0150674. eCollection 2016. https://doi.org/10.1371/journal.pone.0150674
  20. Poli D, Antonucci E, Testa S, et al. A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. Intern Emerg Med. 2014;9(4):443-447.
  21. Esteve-Pastor MA, Roldán V, Valdés M, et al. The SAMe-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2016;14(2):177-187. Epub 2015 Dec 9. https://doi.org/10.1586/14779072.2016.1116941
  22. Zulkifly H, Lip GYH, Lane DA. Use of the SAMe-TT2R2 score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists. A review Heart Rhythm. 2018;15(4):615-623. https://doi.org/10.1016/j.hrthm.2017.11.026
  23. Lin KJ, Singer DE, Glynn R, et al. Prediction Score for Anticoagulation Control Quality Among Older Adults. J Am Heart Assoc. 2017;5:6-10. pii: e006814. https://doi.org/10.1161/JAHA.117.006814
  24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
  25. Kearney L, Ord M, Buxton B, et al. Usefulness of the Charlson co-morbidity index to predict outcomes in patients >60 years old with aortic stenosis during 18 years of follow-up. Am J Cardiol. 2012;110(5):695-701. Epub 2012 May 25. https://doi.org/10.1016/j.amjcard.2012.04.054
  26. Saji M, Katz MR, Ailawadi G, et al. Predictive Value of Age-Adjusted Charlson Co-Morbidity Index for 1-, 3-, and 5-Year Mortality in Patients Requiring Transcatheter Mitral Valve Repair. Am J Cardiol. 2017;120(2):309-314. Epub 2017 Apr 27. https://doi.org/10.1016/j.amjcard.2017.04.022
  27. Cho H, Kim MH, Kim HJ, et al. Development and Validation of the Modified Charlson Comorbidity Index in Incident Peritoneal Dialysis Patients: A National Population-Based Approach. Perit Dial Int. 2017;1-2:37(1):94-102. Epub 2016 Sep 7. https://doi.org/10.3747/pdi.2015.00201
  28. Martínez-Sellés M, Díez-Villanueva P, Sánchez-Sendin D, et al Comorbidity and intervention in octogenarians with severe symptomatic aortic stenosis. Int J Cardiol. 2015;189:61-66. https://doi.org/10.1016/j.ijcard.2015.04.017
  29. Rouaud A, Hanon O, Boureau AS, et al Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study. PLoS One. 2015;10(3):e0119043. https://doi.org/10.1371/journal.pone.0119043
  30. Kropacheva ES, Panchenko EP. Safety of long-term warfarin therapy: algorithms of treatment and determinants of anticoagulation stability. Klinitcist. 2007;4:48-55. (In Russ.)
  31. Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thrombosis and Haemostasis. 2016;116:777-1002.
  32. Arihiro S, Todo K, Koga M, et al Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Int J Stroke. 2016;11(5):565-574. https://doi.org/10.1177/1747493016632239
  33. Başaran Ö, Dogan V, Biteker M, et al Guideline-adherent therapy for stroke prevention in atrial fibrillation in different health care settings: Results from RAMSES study. Eur J Intern Med. 2017;40:50-55. Epub 2017 Feb 24. https://doi.org/10.1016/j.ejim.2017.02.011
  34. Kropacheva ES, Zemlyanskaya OA, Dobrovolsky AB, Panchenko EP. The efficacy of long-term warfarin therapy: the impact on the incidence of ischemic cerebrovascular disorders and clinical predictors of developing such disorders (results of a prospective 10-year follow-up study). Atherotrombosis. 2017;2:115-130. (In Russ.)
  35. Pastori D, Pignatelli P, Saliola M, et al Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. Int J Cardiol. 2015;201:513-516. Epub 2015 Aug 5. https://doi.org/10.1016/j.ijcard.2015.08.054
  36. Panchenko EP, Kropacheva ES. Factors influencing safety of vitamin K antagonist therapy. Vrach. 2006;3:53-58. (In Russ.)
  37. Rose AJ, Hylek EM, Ozonoff A, et al Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010;8(10):2182-2191. https://doi.org/10.1111/j.1538-7836.2010.03996.x
  38. Currie CJ, McEwan P, Emmas C, et al Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. Curr Med Res Opin. 2005;21(12):1905-1913.
  39. Witt DM, Delate T, Clark NP, et al Warped Consortium. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost. 2010;8(4):744-749. https://doi.org/10.1111/j.1538-7836.2010.03756.x
  40. Williams BA, Evans MA, Honushefsky AM, Berger PB. Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation. J Am Heart Assoc. 2017;6(10):pii: e006669. https://doi.org/10.1161/JAHA.117.006669
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.